ScienceDaily (2010-06-03) -- Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, researchers are testing a novel type of antibody called MM-111 in patients with HER2-positive disease who have progressed on standard therapy.
癌症的抗藥改善(標靶?)。
Story Source:
The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by Fox Chase Cancer Center.
No comments:
Post a Comment